[Adverse effects and safety of antimicrobial agents--nephrotoxicity].
Sakamoto
Mitsuo
M
Division of Infectious Diseases and Control, The Jikei University School of Medicine.
D000666:Amphotericin B / Q000009:adverse effects / Q000493:pharmacokinetics / Q000633:toxicity; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000633:toxicity; D000935:Antifungal Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000633:toxicity; D000998:Antiviral Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000633:toxicity; D017245:Foscarnet / Q000009:adverse effects / Q000493:pharmacokinetics / Q000633:toxicity; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D007674:Kidney Diseases / Q000139:chemically induced*; D010455:Peptides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000633:toxicity
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000998:Antiviral Agents; D010455:Peptides; D017245:Foscarnet; D000666:Amphotericin B